Imlygic Side Effects
Generic name: talimogene laherparepvec
Medically reviewed by Drugs.com. Last updated on Feb 14, 2025.
Note: This document provides detailed information about Imlygic Side Effects associated with talimogene laherparepvec. Some dosage forms listed on this page may not apply specifically to the brand name Imlygic.
Applies to talimogene laherparepvec: injection suspension.
Precautions
Your doctor will check your progress closely while you are receiving this medicine. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to receive it. Blood tests may be needed to check for unwanted effects.
Using this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. If you think you have become pregnant while using the medicine, tell your doctor right away.
This medicine can spread to other areas of the body or to other people (eg, household members, caregiver, or persons sharing the same bed). To avoid spreading the medicine:
- Avoid direct contact between your treatment sites, dressings, body fluids or close contacts. Do not touch or scratch the treatment sites.
- Wear gloves when putting on or changing your dressings.
- Cover the treatment sites with airtight and watertight dressings for at least 1 week after each treatment.
- If the dressing comes loose or falls off, use a new, clean dressing to replace it.
- Place all used dressings and cleaning materials in a sealed plastic bag and throw them in the trash can.
This medicine may cause herpes infections (including cold sores). Tell your doctor right away if you have pain, burning, or tingling in a blister around the mouth or genitals or on the fingers or ears, confusion, extreme drowsiness, blurred vision, eye pain, sensitivity to light, or weakness in your arms or legs.
This medicine may cause delayed healing at the injection site. It is more likely to occur if you had previous radiation treatment at the injection site or lesions. Tell your doctor right away if you have infection or delayed healing of the injection sites.
Immune-mediated events may occur while receiving this medicine. These include glomerulonephritis, pneumonitis, psoriasis, vasculitis, or vitiligo. Tell your doctor if you have bloody or cloudy urine, swelling of the feet or lower legs, weight gain, fever, sores, welting, or blisters, or red, scaling, or crusted skin.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
Serious side effects of Imlygic
Along with its needed effects, talimogene laherparepvec (the active ingredient contained in Imlygic) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking talimogene laherparepvec:
More common side effects
Incidence not known
- break in the skin, especially associated with blue-black discoloration, swelling, or drainage of fluid
- burning or stinging of the skin
- painful cold sores or blisters on the lips, nose, eyes, or genitals
Other side effects of Imlygic
Some side effects of talimogene laherparepvec may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
- abdominal or stomach pain
- difficulty having a bowel movement (stool)
- difficulty with moving
- dizziness
- muscle pain or stiffness
- pain in the arms or legs
- weight loss
See also:
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Dacarbazine
Dacarbazine is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Ipilimumab
ipilimumab (Yervoy) is an immunotherapy used for melanoma, renal cell carcinoma, non-small cell ...
Dabrafenib
Dabrafenib is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer, solid ...
Trametinib
Trametinib is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer, solid ...
For healthcare professionals
Applies to talimogene laherparepvec: injectable suspension.
General adverse events
The most commonly reported (25% or more) adverse drug reactions were fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain.
Pyrexia, chills, and influenza-like illness can occur at any time during treatment, but were more frequent during the first 3 months.
Most adverse reactions were mild or moderate in severity and generally resolved within 72 hours.
Cellulitis was the most common grade 3 or higher adverse reaction.[Ref]
Other
- Very common (10% or more): Fatigue (50.3%), chills (48.6%), pyrexia (42.8%), influenza-like illness (30.5%), injection site pain (27.7%)
- Common (1% to 10%): Decreased weight
- Frequency not reported: Herpetic infection, injection site complications (cellulitis, systemic bacterial infection, impaired healing)[Ref]
Gastrointestinal
- Very common (10% or more): Nausea (35.6%), vomiting (21.2%), diarrhea (18.8%), constipation (11.6%)
- Common (1% to 10%): Abdominal pain
- Frequency not reported: Oral herpes[Ref]
Nervous system
- Very common (10% or more): Headache (18.8%)
- Common (1% to 10%): Dizziness[Ref]
Musculoskeletal
Immunologic
- Frequency not reported: Immune-mediated events (glomerulonephritis, vasculitis, pneumonitis, psoriasis, vitiligo)[Ref]
Oncologic
- Frequency not reported: Plasmacytoma[Ref]
Respiratory
- Common (1% to 10%): Oropharyngeal pain[Ref]
Metabolic
- Common (1% to 10%): Decreased weight[Ref]
References
1. (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
More about Imlygic (talimogene laherparepvec)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Imlygic side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.